Abstract
RNA interference (RNAi), as a novel technique in which RNA molecules limit or silence the gene expression, is currently a hot research topic for producing novel therapeutic materials for challenging diseases. In the development of RNAi-based therapies, nanoscale particles, with a varying diameter along with facile modification methods that can mediate effective RNAi with targeting potential, are gaining wide interest. The nanotechnology itself has tremendous potential in the field of healthcare, especially for the development of better pharmaceuticals. Nano-enabled delivery has shown great success in the delivery of RNAi based therapeutics to specific locations in the body. Especially, siRNAs show great potential for use in nucleic acid therapeutics because of their potent and specific RNAi-triggering activity. This review summarizes the advanced nanocarriers such as solid lipid nanoparticles, gold nanoparticles, silver nanoparticles, iron oxide nanoparticles, polymeric nanoparticles, nanotransformers and curdlan nanoparticles with special emphasis on various aspects of siRNA-based therapeutics.
Keywords: Nanotechnology, RNA interference, siRNA, polymeric nanoparticles, metallic nanoparticles, nanotransformers, curdlan nanoparticles.
Current Pharmaceutical Design
Title:Budding Alliance of Nanotechnology in RNA Interference Therapeutics
Volume: 24 Issue: 23
Author(s): Akshant Kumawat, Prachi Dapse, Narendra Kumar, Dinesh Kumar Mishra, Rahul Maheshwari, Pallab Bhattacharya*Rakesh Kumar Tekade
Affiliation:
- National Institute of Pharmaceutical Education and Research (NIPER)-Ahmedabad, (An Institute of National Importance, Government of India), Department of Pharmaceuticals, Ministry of Chemicals and Fertilizers, Palaj, Opposite Air Force Station, Gandhinagar, Gujarat-382355,India
Keywords: Nanotechnology, RNA interference, siRNA, polymeric nanoparticles, metallic nanoparticles, nanotransformers, curdlan nanoparticles.
Abstract: RNA interference (RNAi), as a novel technique in which RNA molecules limit or silence the gene expression, is currently a hot research topic for producing novel therapeutic materials for challenging diseases. In the development of RNAi-based therapies, nanoscale particles, with a varying diameter along with facile modification methods that can mediate effective RNAi with targeting potential, are gaining wide interest. The nanotechnology itself has tremendous potential in the field of healthcare, especially for the development of better pharmaceuticals. Nano-enabled delivery has shown great success in the delivery of RNAi based therapeutics to specific locations in the body. Especially, siRNAs show great potential for use in nucleic acid therapeutics because of their potent and specific RNAi-triggering activity. This review summarizes the advanced nanocarriers such as solid lipid nanoparticles, gold nanoparticles, silver nanoparticles, iron oxide nanoparticles, polymeric nanoparticles, nanotransformers and curdlan nanoparticles with special emphasis on various aspects of siRNA-based therapeutics.
Export Options
About this article
Cite this article as:
Kumawat Akshant , Dapse Prachi , Kumar Narendra , Mishra Kumar Dinesh, Maheshwari Rahul , Bhattacharya Pallab *, Tekade Kumar Rakesh , Budding Alliance of Nanotechnology in RNA Interference Therapeutics, Current Pharmaceutical Design 2018; 24 (23) . https://dx.doi.org/10.2174/1381612824666180807113948
DOI https://dx.doi.org/10.2174/1381612824666180807113948 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements